PositiveID (OTC:PSID) licensed its iGlucose technology for a cool $2 million to Smart Glucose Meter Corp. as part of its shift toward molecular diagnostics.
The deal, valued at up to $2 million, could be worth up to $5 per patient per year for Smart Glucose Meter, according to a regulatory filing.